Guardant Health, Inc. announced a partnership with actor and health advocate James Van Der Beek to increase awareness about colorectal cancer (CRC) screening and the Shield blood test. Van Der Beek, who went public with his stage 3 CRC diagnosis in November 2024, aims to encourage others to get screened.
The Shield blood test, approved by the U.S. Food and Drug Administration (FDA) last year, offers a convenient and more pleasant option for CRC screening for eligible individuals aged 45 and older. Van Der Beek highlighted that early detection is crucial, as the five-year survival rate is over 90% when CRC is caught early.
AmirAli Talasaz, Guardant Health co-CEO, stated that the partnership aims to ensure everyone who should be screened for CRC gets screened, with the Shield blood test being a major step towards making screening more accessible. The National Comprehensive Cancer Network recently included Shield in its updated CRC screening guidelines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.